Purchase Order 75N91018P00729

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for an EVOS M5000 imaging system, valued at $21,875.59, on August 5, 2026. The order carries no set-aside designation and is priced as firm fixed price. Place of performance is Carlsbad, California. Ultimate completion is scheduled for August 4, 2027.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for an EVOS FL Auto 2 Imaging System on December 14, 2017, with a ceiling value of $15,185.81. The order was completed on the same date under firm fixed pricing with no set-aside. Place of performance is Carlsbad, California. Life Technologies Corporation operates as Thermo Fisher Scientific.</p>

The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $24,095.00 on August 6, 2021, for EVOS M5000 DSS equipment with a one-year reorder exchange provision. The order was issued to administratively de-obligate unexpiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) prior to the September 30, 2021 close of the fiscal year period of availability. Performance occurs at Grand Island, New York. The purchase order carries firm...

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $12,768.84 on September 11, 2018, with completion scheduled for September 18, 2019. Pricing is fixed-price with economic price adjustment. Place of performance is Bethesda, Maryland. The source does not identify the specific items or services procured under this order.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for lab equipment valued at $24,628.60 on September 22, 2020, with completion on December 22, 2020. Performance takes place in Bethesda, Maryland. The order is firm fixed price with no small business set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Biovision Technologies, Inc., a small business, for $23,860.40 on September 7, 2017, with an ultimate completion date of October 8, 2017. Place of performance is Bethesda, Maryland. The order calls for precision scientific imaging equipment or related optical/microscopy instrumentation. Pricing is firm fixed price.</p>

<p>The National Institutes of Health Clinical Center awarded a purchase order to Life Technologies Corporation for EVO imaging equipment on July 6, 2020, with a ceiling value of $24,018.67. Place of performance is Carlsbad, California. The order carries a firm fixed price and was scheduled for ultimate completion on August 5, 2020. No set-aside applied to this acquisition.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $5,611.84 on July 11, 2017, with ultimate completion on August 16, 2018. No set-aside was used. Performance occurs in Bethesda, Maryland. The order is for laboratory instrumentation, reagents, consumables, or maintenance services typical of Life Technologies' federal portfolio in life-sciences research and diagnostic infrastructure. Pricing is firm fixed price.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $20,776.50 on September 5, 2019, with completion by October 5, 2019. Place of performance is Carlsbad, California. The order represents a firm fixed-price, commercial purchase of laboratory instrumentation, reagents, or consumables—Life Technologies' core federal offering in genetic analysis and molecular biology. No set-aside was applied.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for biologicals valued at $13,401.67 on March 12, 2020, with an ultimate completion date of April 9, 2020. Place of performance is Bethesda, Maryland. The order is firm fixed price with no set-aside designation.</p>